Summary of those studies reporting on SRS for patients with ≥5 brain metastases that met prespecified inclusion criteria
| Author (year) . | Range of Metastases/ Total Volume/ Number of Patients . | Key Patient Inclusion Criteria . | Median Follow-up . | Local Recurrence . | Distant Brain Failure (DBF)/ Time to DBF . | Overall Survival . |
|---|---|---|---|---|---|---|
| Yamamoto et al22 (2014) | 5–10 mets (median 6)/ mean = 3.54 cc/208 | No single met >3 cm or 10 cc Cumulative tumor volume ≤15 cc KPS ≥70 (100% no prior WBRT) | 12 mo | 1 y = 6.5% 2y = 9.8% | 1 y = 63.8% 2 y = 72%/ median = 8.04 mo | Median = 10.8 mo |
| Salvetti et al23 (2013) | 5–15 (median 7)/ median per patient = 6.12 cc/ 96 | Histology other than small cell or unknown primary KPS≥70 (53% no prior WBRT) | 4.1 mo | 1 y = 15.2% 2 y = 25.1% | Crude: 41.0% /NR | 5–9 mets = median 4.8 mo, 10–15 mets = median 3.4 mo |
| Rava et al24 (2013) | 10–34 (mean 11)/NR/53 | KPS≥70 (36% no prior WBRT) | NR | Crude: 13.2% | 1 y = 90%/ median = 3 mo | median = 6.5 mo |
| Mohammadi et al25 (2012) | 5–20 (median 6)/ median = 3.2 cc/178 | KPS≥70 (46% no prior WBRT) | 6.2 mo | Crude: 3% | Crude: 40%/ median = 2.1 mo | median = 6.7 mo |
| Grandhi et al26 (2012) | 10–28 (mean 13.2)/ median = 4.86 cc/61 | 77% KPS 90–100 (37.7% no prior WBRT) | 4 mo | 1 y = 58.3% | 1 y = 77.6%/ median = 3 mo | Median = 4 mo |
| Lee et al27 (2011) | 4–14/NR /36 | Median KPS 90 (range, 60–80) (80.6% no prior WBRT) | 4.5 mo | 9 mo = 15.8% | Crude = 22.2%/ median = 4 mo | Median: 4.5 mo |
| Chang et al28 (2010) | Group 2: 6–10/NR /58 Group 3: 11–15 /NR/17 Group 4: >15/NR/33 | KPS≥70 RPA 1 or 2 (Group 4, 42.4% had prior WBRT) | *Group 2: 10.7 moGroup 3: 12.3 moGroup 4: 8 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 89%(Group 4, 36.8% of the 57.6% developing distantmets were within 3 mo) | *Group 2: 1 y = 47.2%/median = 8.8 moGroup 3: 1 y = 53.1%/median = 5.3 mo Group 4: 1 y = 80.3%/ median = 5.0 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 88% |
| Kim et al29 (2008) | 10–37 (mean 16.6)/mean 10.9 cc/26 | KPS≥70 (69% prior/ adjuvant WBRT) | NR | 6 mo = 20.6% | 6 mo = 26.9% /NR | Median = 7.8 mo |
| Bhatnagar et al30 (2006) | 4–18 (median 5)/NR/205 | >3 brain mets (83% prior or adjuvant WBRT) | Mean = 8 mo | 1 y = 29% | 1 y = 43%/ median = 9 mo | Median = 8 mo |
| Nam et al31 ( 2005) | 4–10/NR/46 | Not specified for this cohort | Mean = 13.3 mo | 1 y = 30.5% | 1 y = 78.1%/NR | Median = 5.4 mo |
| Author (year) . | Range of Metastases/ Total Volume/ Number of Patients . | Key Patient Inclusion Criteria . | Median Follow-up . | Local Recurrence . | Distant Brain Failure (DBF)/ Time to DBF . | Overall Survival . |
|---|---|---|---|---|---|---|
| Yamamoto et al22 (2014) | 5–10 mets (median 6)/ mean = 3.54 cc/208 | No single met >3 cm or 10 cc Cumulative tumor volume ≤15 cc KPS ≥70 (100% no prior WBRT) | 12 mo | 1 y = 6.5% 2y = 9.8% | 1 y = 63.8% 2 y = 72%/ median = 8.04 mo | Median = 10.8 mo |
| Salvetti et al23 (2013) | 5–15 (median 7)/ median per patient = 6.12 cc/ 96 | Histology other than small cell or unknown primary KPS≥70 (53% no prior WBRT) | 4.1 mo | 1 y = 15.2% 2 y = 25.1% | Crude: 41.0% /NR | 5–9 mets = median 4.8 mo, 10–15 mets = median 3.4 mo |
| Rava et al24 (2013) | 10–34 (mean 11)/NR/53 | KPS≥70 (36% no prior WBRT) | NR | Crude: 13.2% | 1 y = 90%/ median = 3 mo | median = 6.5 mo |
| Mohammadi et al25 (2012) | 5–20 (median 6)/ median = 3.2 cc/178 | KPS≥70 (46% no prior WBRT) | 6.2 mo | Crude: 3% | Crude: 40%/ median = 2.1 mo | median = 6.7 mo |
| Grandhi et al26 (2012) | 10–28 (mean 13.2)/ median = 4.86 cc/61 | 77% KPS 90–100 (37.7% no prior WBRT) | 4 mo | 1 y = 58.3% | 1 y = 77.6%/ median = 3 mo | Median = 4 mo |
| Lee et al27 (2011) | 4–14/NR /36 | Median KPS 90 (range, 60–80) (80.6% no prior WBRT) | 4.5 mo | 9 mo = 15.8% | Crude = 22.2%/ median = 4 mo | Median: 4.5 mo |
| Chang et al28 (2010) | Group 2: 6–10/NR /58 Group 3: 11–15 /NR/17 Group 4: >15/NR/33 | KPS≥70 RPA 1 or 2 (Group 4, 42.4% had prior WBRT) | *Group 2: 10.7 moGroup 3: 12.3 moGroup 4: 8 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 89%(Group 4, 36.8% of the 57.6% developing distantmets were within 3 mo) | *Group 2: 1 y = 47.2%/median = 8.8 moGroup 3: 1 y = 53.1%/median = 5.3 mo Group 4: 1 y = 80.3%/ median = 5.0 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 88% |
| Kim et al29 (2008) | 10–37 (mean 16.6)/mean 10.9 cc/26 | KPS≥70 (69% prior/ adjuvant WBRT) | NR | 6 mo = 20.6% | 6 mo = 26.9% /NR | Median = 7.8 mo |
| Bhatnagar et al30 (2006) | 4–18 (median 5)/NR/205 | >3 brain mets (83% prior or adjuvant WBRT) | Mean = 8 mo | 1 y = 29% | 1 y = 43%/ median = 9 mo | Median = 8 mo |
| Nam et al31 ( 2005) | 4–10/NR/46 | Not specified for this cohort | Mean = 13.3 mo | 1 y = 30.5% | 1 y = 78.1%/NR | Median = 5.4 mo |
Abbreviations: mets, metastases; NR, not reported; * data provided by corresponding author
Summary of those studies reporting on SRS for patients with ≥5 brain metastases that met prespecified inclusion criteria
| Author (year) . | Range of Metastases/ Total Volume/ Number of Patients . | Key Patient Inclusion Criteria . | Median Follow-up . | Local Recurrence . | Distant Brain Failure (DBF)/ Time to DBF . | Overall Survival . |
|---|---|---|---|---|---|---|
| Yamamoto et al22 (2014) | 5–10 mets (median 6)/ mean = 3.54 cc/208 | No single met >3 cm or 10 cc Cumulative tumor volume ≤15 cc KPS ≥70 (100% no prior WBRT) | 12 mo | 1 y = 6.5% 2y = 9.8% | 1 y = 63.8% 2 y = 72%/ median = 8.04 mo | Median = 10.8 mo |
| Salvetti et al23 (2013) | 5–15 (median 7)/ median per patient = 6.12 cc/ 96 | Histology other than small cell or unknown primary KPS≥70 (53% no prior WBRT) | 4.1 mo | 1 y = 15.2% 2 y = 25.1% | Crude: 41.0% /NR | 5–9 mets = median 4.8 mo, 10–15 mets = median 3.4 mo |
| Rava et al24 (2013) | 10–34 (mean 11)/NR/53 | KPS≥70 (36% no prior WBRT) | NR | Crude: 13.2% | 1 y = 90%/ median = 3 mo | median = 6.5 mo |
| Mohammadi et al25 (2012) | 5–20 (median 6)/ median = 3.2 cc/178 | KPS≥70 (46% no prior WBRT) | 6.2 mo | Crude: 3% | Crude: 40%/ median = 2.1 mo | median = 6.7 mo |
| Grandhi et al26 (2012) | 10–28 (mean 13.2)/ median = 4.86 cc/61 | 77% KPS 90–100 (37.7% no prior WBRT) | 4 mo | 1 y = 58.3% | 1 y = 77.6%/ median = 3 mo | Median = 4 mo |
| Lee et al27 (2011) | 4–14/NR /36 | Median KPS 90 (range, 60–80) (80.6% no prior WBRT) | 4.5 mo | 9 mo = 15.8% | Crude = 22.2%/ median = 4 mo | Median: 4.5 mo |
| Chang et al28 (2010) | Group 2: 6–10/NR /58 Group 3: 11–15 /NR/17 Group 4: >15/NR/33 | KPS≥70 RPA 1 or 2 (Group 4, 42.4% had prior WBRT) | *Group 2: 10.7 moGroup 3: 12.3 moGroup 4: 8 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 89%(Group 4, 36.8% of the 57.6% developing distantmets were within 3 mo) | *Group 2: 1 y = 47.2%/median = 8.8 moGroup 3: 1 y = 53.1%/median = 5.3 mo Group 4: 1 y = 80.3%/ median = 5.0 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 88% |
| Kim et al29 (2008) | 10–37 (mean 16.6)/mean 10.9 cc/26 | KPS≥70 (69% prior/ adjuvant WBRT) | NR | 6 mo = 20.6% | 6 mo = 26.9% /NR | Median = 7.8 mo |
| Bhatnagar et al30 (2006) | 4–18 (median 5)/NR/205 | >3 brain mets (83% prior or adjuvant WBRT) | Mean = 8 mo | 1 y = 29% | 1 y = 43%/ median = 9 mo | Median = 8 mo |
| Nam et al31 ( 2005) | 4–10/NR/46 | Not specified for this cohort | Mean = 13.3 mo | 1 y = 30.5% | 1 y = 78.1%/NR | Median = 5.4 mo |
| Author (year) . | Range of Metastases/ Total Volume/ Number of Patients . | Key Patient Inclusion Criteria . | Median Follow-up . | Local Recurrence . | Distant Brain Failure (DBF)/ Time to DBF . | Overall Survival . |
|---|---|---|---|---|---|---|
| Yamamoto et al22 (2014) | 5–10 mets (median 6)/ mean = 3.54 cc/208 | No single met >3 cm or 10 cc Cumulative tumor volume ≤15 cc KPS ≥70 (100% no prior WBRT) | 12 mo | 1 y = 6.5% 2y = 9.8% | 1 y = 63.8% 2 y = 72%/ median = 8.04 mo | Median = 10.8 mo |
| Salvetti et al23 (2013) | 5–15 (median 7)/ median per patient = 6.12 cc/ 96 | Histology other than small cell or unknown primary KPS≥70 (53% no prior WBRT) | 4.1 mo | 1 y = 15.2% 2 y = 25.1% | Crude: 41.0% /NR | 5–9 mets = median 4.8 mo, 10–15 mets = median 3.4 mo |
| Rava et al24 (2013) | 10–34 (mean 11)/NR/53 | KPS≥70 (36% no prior WBRT) | NR | Crude: 13.2% | 1 y = 90%/ median = 3 mo | median = 6.5 mo |
| Mohammadi et al25 (2012) | 5–20 (median 6)/ median = 3.2 cc/178 | KPS≥70 (46% no prior WBRT) | 6.2 mo | Crude: 3% | Crude: 40%/ median = 2.1 mo | median = 6.7 mo |
| Grandhi et al26 (2012) | 10–28 (mean 13.2)/ median = 4.86 cc/61 | 77% KPS 90–100 (37.7% no prior WBRT) | 4 mo | 1 y = 58.3% | 1 y = 77.6%/ median = 3 mo | Median = 4 mo |
| Lee et al27 (2011) | 4–14/NR /36 | Median KPS 90 (range, 60–80) (80.6% no prior WBRT) | 4.5 mo | 9 mo = 15.8% | Crude = 22.2%/ median = 4 mo | Median: 4.5 mo |
| Chang et al28 (2010) | Group 2: 6–10/NR /58 Group 3: 11–15 /NR/17 Group 4: >15/NR/33 | KPS≥70 RPA 1 or 2 (Group 4, 42.4% had prior WBRT) | *Group 2: 10.7 moGroup 3: 12.3 moGroup 4: 8 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 89%(Group 4, 36.8% of the 57.6% developing distantmets were within 3 mo) | *Group 2: 1 y = 47.2%/median = 8.8 moGroup 3: 1 y = 53.1%/median = 5.3 mo Group 4: 1 y = 80.3%/ median = 5.0 mo | *Group 2: 1 y = 83% Group 3: 1 y = 92%Group 4: 1 y = 88% |
| Kim et al29 (2008) | 10–37 (mean 16.6)/mean 10.9 cc/26 | KPS≥70 (69% prior/ adjuvant WBRT) | NR | 6 mo = 20.6% | 6 mo = 26.9% /NR | Median = 7.8 mo |
| Bhatnagar et al30 (2006) | 4–18 (median 5)/NR/205 | >3 brain mets (83% prior or adjuvant WBRT) | Mean = 8 mo | 1 y = 29% | 1 y = 43%/ median = 9 mo | Median = 8 mo |
| Nam et al31 ( 2005) | 4–10/NR/46 | Not specified for this cohort | Mean = 13.3 mo | 1 y = 30.5% | 1 y = 78.1%/NR | Median = 5.4 mo |
Abbreviations: mets, metastases; NR, not reported; * data provided by corresponding author
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
